Suchergebnisse - (Person:"Curtin, Nicola")

PubPharm (23)

1

Poly(ADP-ribose) polymerase inhibition : past, present and future

enthalten in: Nature reviews. Drug discovery | 2020

von Curtin, N. | Szabo, C.

2

Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors

enthalten in: Biochemical pharmacology | 2019

von Mukhopadhyay, A. | Drew, Y. | Matheson, E. | +4

3

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

enthalten in: Cancer discovery | 2017

von de Bono, J. | Ramanathan, R. | Mina, L. | +13

4

Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis : Mechanism and Potential Role for PARP Inhibitors

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2016

von Kotsopoulos, I. | Kucukmetin, A. | Mukhopadhyay, A. | +2

5

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

enthalten in: Oncotarget | 2015

von Herriott, A. | Tudhope, S. | Junge, G. | +13

6

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma

enthalten in: Current opinion in oncology | 2014

von Vormoor, B. | Curtin, N.

7

PARP inhibitors for anticancer therapy

enthalten in: Biochemical Society transactions | 2014

von Curtin, N.

8

PARP inhibitors target ATM+p53-defective gastric cancer

enthalten in: Cell cycle (Georgetown, Tex.) | 2014

von Curtin, N.

CommentOn: Cell Cycle. 2014;13(13):2129-37. - PMID 24841718

9

Therapeutic applications of PARP inhibitors : anticancer therapy and beyond

enthalten in: Molecular aspects of medicine | 2013

von Curtin, N. | Szabo, C.

10

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2

enthalten in: Journal of the National Cancer Institute | 2011

von Drew, Y. | Mulligan, E. | Vong, W. | +9